On its third quarter of 2026 earnings call, held on Nov. 5, 2026, Organogenesis (ORGO -3.46%) reported sequential revenue growth despite severe policy-driven industry contraction. Regulatory changes to Medicare reimbursement drastically shrank the broader market, making profitability dependent on commercial execution and scientific evidence. Three things management said stand out.1. Shifting Reimbursement Policies Are Clearing Out CompetitorsFederal policy changes disrupted the skin substitute market, but l ...